Extra ‘triple therapy’ drug for type 2 diabetes

NICE has published final guidance recommending dapagliflozin for treating type 2 diabetes in ‘triple therapy’. Dapagliflozin can be added as a third drug where two drugs for type 2 diabetes are not controlling a person’s blood sugar.

 Professor Carole Longson, director of the NICE centre for health technology evaluation, said: “Having a range of drug options makes it easier to tailor treatments for type 2 diabetes to each person’s individual needs. This new guidance recommends dapagliflozin in triple therapy – only in combination with metformin and a sulfonylurea – which will widen the choice available for people whose diabetes isn’t well controlled with two drugs.”

 

 

Other news

Upcoming Events

QIST 2017

The Marriott Hotel Gosforth Newcastle
17th - 18th October

MEDICA

Düsseldorf
13 - 16 November 2017

IDSc CONFERENCE 2016

The Hilton, Blackpool
27th - 29th November

Latest Issue

Clinical Services Journal

Clinical Services Journal

Sep 2017

Being confident that your wipes work

Register now to apply for regular copies of Clinical Services Journal and free access to premium content, as well as our regular newsletters.

CSJ Supplements

CSJ Supplements

Aug 2017

Technology with the vision to make surgery better

Register now to apply for regular copies of CSJ Supplements and free access to premium content, as well as our regular newsletters.